New Drugs in the Ulcerative Colitis Pipeline: Prometheus Unbound - Gastroenterology
Next generation of small molecules in inflammatory bowel disease | Gut
Arena Pharmaceuticals Inc 2020 Current Report 8-K
Etrasimod in Ulcerative Colitis: Promising Phase 2 Results - Gastroenterology Advisor
Arena Pharmaceuticals Inc (ARNA)
Frontiers | Frontiers in Drug Research and Development for Inflammatory Bowel Disease | Pharmacology
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis - Gastroenterology
Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective | Pharmacology
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Col
Arena Pharmaceuticals Inc 2020 Current Report 8-K
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects | SpringerLink
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
etrasimod | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects | SpringerLink
Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease: Trends in Molecular Medicine
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects | SpringerLink
S1P mechanisms of action. This figure was made with Servier Medical Art... | Download Scientific Diagram
Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statement - ARENA PHARMACEUTICALS INC - October 26, 2020
arna-10k_20181231.htm
The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental
Immunotherapy in inflammatory bowel disease: Novel and emerging treatments
Novel Targeted Therapies for Inflammatory Bowel Disease: Trends in Pharmacological Sciences
